Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0608 • ACR Convergence 2025
Strong Correlation Between SLEDAI and SLE-DAS in the Spanish Population: Assessment of Discordant Patients
Elena Heras Recuero¹, Antia Garcia Fernandez², Cristina Gomez-Moreno³, Ivan Ferraz Amaro⁴, Javier Llorca⁵ and Miguel A. González-Gay⁶, ¹Hospital Fundacion Jimenez Dias, Madrid, Spain, ²Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, ³Fundacion Jiménez Díaz School of Nursing, Madrid, Autonomous University Madrid, Madrid, Spain, ⁴Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁵CIBER Epidemiología y Salud Pública (CIBERESP) and Department of Medical and Surgical Sciences, University of Cantabria, Santander, Spain, ⁶Department of Rheumatology and Joint and Bone Research Unit, Hospital Universitario Fundación Jiménez Díaz, and Instituto de Investigación Sanitaria-Fundación Jiménez Díaz, Madrid, Spain, and Medicine and Psychiatry Department, University of Cantabria, Santander, Spain
Background/Purpose: Assessing disease activity in systemic lupus erythematosus (SLE) is essential for effective treatment. SLEDAI-2K uses dichotomous items, while SLE-DAS incorporates both dichotomous and continuous…
Abstract Number: 0885 • ACR Convergence 2025
MAIT cell-mediated immune modulation in lupus: antigen-driven expansion as a protective strategy
Grace Crossland¹, lennard Ostendorf², Vianey Chavez¹, Lindsay Mendyka¹, Deepak Rao³ and Sladjana Skopelja-Gardner¹, ¹Dartmouth College, Lebanon, NH, ²Brigham and Women's Hospital, Boston, ³Brigham and Women's Hospital, Boston, MA
Background/Purpose: Systemic lupus erythematosus (SLE) is a leading cause of death for young women, and over 75% of SLE patients experience skin manifestations – cutaneous…
Abstract Number: 0791 • ACR Convergence 2025
Disagreements in Disease Activity Measures in an Evaluation of SLE Outcome Measures in Telemedicine
Leila Khalili¹, Cynthia Aranow², Mimi Kim³, Diane Kamen⁴, Cristina Arriens⁵, Alberto Nordmann-Gomes⁶, Maya Souvignier⁶, Wei Tang⁷, Stephen Suh⁸, Maria Dall'Era⁹, Meghan mackay¹⁰ and Anca Askanase¹, ¹Columbia University Medical Center, New York, NY, ²Institute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, NY, ³Albert Einstein College of Medicine, Bronx, NY, ⁴Medical University of South Carolina, Johns Island, SC, ⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Columbia University Irving Medical Center, New York, NY, ⁷Westchester Medical Center, Valhalla, NY, ⁸Columbia University Irving Medical Center, New York City, NY, ⁹Division of Rheumatology, University of California, San Francisco, CA, ¹⁰Feinstein Institutes for Medical Research, Manhasset, NY
Background/Purpose: We previously described the top-line results of our study and the high correlations between virtual SLE disease activity measures (DAM) and those obtained during…
Abstract Number: 0196 • ACR Convergence 2025
Increasing Timely Rheumatology Evaluation for High Risk Lupus Patients
Steven Taylor¹ and Elena Weinstein², ¹University of Colorado, Denver, CO, ²University of Colorado, Englewood, CO
Background/Purpose: The rheumatology workforce shortage presents many challenges to the delivery of rheumatology care. Improving timely access to rheumatology for patients with life or organ…
Abstract Number: 1510 • ACR Convergence 2025
Biomarker landscape for neuropsychiatric involvement in patient with systemic lupus erythematosus
Sitian Zang¹, Ranran Yao² and Zhanguo Li³, ¹Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing, China (People's Republic), ²Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China (People's Republic), ³Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, Beijing, Beijing, China (People's Republic)
Background/Purpose: Systemic lupus erythematosus (SLE) is a multifactorial autoimmune disease result in substantial organs or systems damage or even fatal. The estimated number of global…
Abstract Number: 2665 • ACR Convergence 2025
Preexisting Antibodies Against Vaccine Antigens Are Preserved In Patients With Systemic Lupus Erythematosus and Sjögren’s Disease Upon Ianalumab Treatment While Autoantibodies Decline
Thomas Dörner¹, Nan Shen², Thomas Grader-Beck³, Caroline Walter⁴, Catherine Wioland⁴, Celine Rauld⁴, Patrick Schmutz⁴, Simone Riek⁴, Wolfgang Hueber⁵, CAROLE SIPS⁶, Stephen Oliver⁴, Carol Lau⁷, Claire Bonal⁶ and Isabelle Isnardi⁸, ¹Charite Universitétsmedizin Berlin, Germany and DRFZ, Berlin, Berlin, Germany, ²Shanghai Jiang Tong University School of Medicine, Shanghai, China (People's Republic), ³Johns Hopkins, Reisterstown, MD, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Novartis Pharmaceuticals, Basel, Switzerland, ⁶Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland, ⁷Novartis Pharmaceuticals Corporation, East Hanover, ⁸Novartis, Gueberschwihr, France
Background/Purpose: Ianalumab, an afucosylated mAb, depletes B cells via enhanced antibody (Ab)-dependent cellular cytotoxicity and blocks B cell-activating factor (BAFF): BAFF-receptor (BAFF-R) mediated signals.1 It…
Abstract Number: 2581 • ACR Convergence 2025
From Skin to Kidney: Neutrophil-Mediated Crosstalk Links Cutaneous Injury to Renal Inflammation and Vascular Remodeling in Lupus
Angelique Cortez¹, Lindsay Mendyka², Paola Garcia³, Elizabeth Nowak¹, Fred Kolling⁴, Lucas Salas¹, Christopher Burns⁵, Andrea Fava⁶ and Sladjana Skopelja-Gardner⁷, ¹Dartmouth College, Lebanon, NH, ²Dartmouth College, Lyme, NH, ³St. Mary's University, San Antonio, TX, ⁴Geisel School of Medicine at Dartmouth, Lebanon, NH, ⁵Dartmouth Health, Lebanon, NH, ⁶Johns Hopkins University, Baltimore, MD, ⁷Dartmouth Geisel School of Medicine, Lebanon, NH
Background/Purpose: The majority of SLE patients are sensitive to ultraviolet light (UV), which can lead to local and systemic inflammation, including lupus nephritis (LN) flares.…
Abstract Number: 2464 • ACR Convergence 2025
IMC-002 (IMM0306), a First-in-Class Bi-specific Fusion Protein, Demonstrates Improvements in Systemic Lupus Erythematosus (SLE) Disease Activity Measures and Biomarkers in Patients with Moderate to Severe Active SLE in the Open-label Phase 1b/2 Study
Haihong Yao¹, Wenzhi Tian², Qian Zheng², Min Chen², Guoping Jiang³, Zhichun Liu⁴, Yingkun Nie⁵, Rui Wu⁶, Zhaohui Zheng⁷ and Zhanguo Li¹, ¹Peking University People's Hospital, Beijing, China (People's Republic), ²ImmuneCare Biopharmaceuticals (Shanghai) Co.,Ltd, Shanghai, China (People's Republic), ³Jilin Province People's Hospital, Changchun, China (People's Republic), ⁴The Second Affiliated Hospital of Soochow, Suzhou, China (People's Republic), ⁵The Second Affiliated Hospital of Harbin Medical University, Haerbin, China (People's Republic), ⁶The First Affiliated Hospital of Nanchang University, Nanchang, China (People's Republic), ⁷The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China (People's Republic)
Background/Purpose: Deep B cell depletion has been confirmed to be the main mechanism for complete clinical response of SLE patients. We analyzed the peripheral blood…
Abstract Number: 2445 • ACR Convergence 2025
Achievement of Treat to Target Measures With Upadacitinib in Patients With Systemic Lupus Erythematosus: Phase 2 Randomized SLEek Clinical Trial Results
Eric Morand¹, Joan Merrill², Martin Aringer³, Zahi Touma⁴, Richard Furie⁵, Karim Masri⁶, Christopher Saffore⁷, Ling Cheng⁸ and Ronald van Vollenhoven⁹, ¹Centre for Inflammatory Diseases, Monash University and Monash Health, Melbourne, Victoria, Australia, ²Oklahoma Medical Research Foundation, Oklahoma City ⁷³¹⁰⁴, OK, ³University Medical Center, Dresden, Germany, ⁴University of Toronto, Toronto, ON, Canada, ⁵Division of Rheumatology, Northwell Health, Great Neck, NY, ⁶AbbVie Inc., North Chicago, IL, ⁷AbbVie Inc., waukegan, IL, ⁸AbbVie, North, IL, ⁹Department of Rheumatology, Amsterdam University Medical Centre, Amsterdam, Netherlands
Background/Purpose: Achievement of treat-to-target measures Lupus Low Disease Activity State (LLDAS) and Definition of Remission in SLE (DORIS) has been associated with improved outcomes and…
Abstract Number: 2429 • ACR Convergence 2025
mHealth-enabled Peer Coaching for Fatigue in Systemic Lupus Erythematosus (SLE): Preliminary Results from the Restore Energy, Activity Can Help (REACH) Pilot Randomized Controlled Trial
Shanthini Kasturi¹, Erin Morrissey¹, Anna Deck², Nina Gulati², Zoe Gilbard², Kiran Singh¹, Monique Gore-Massy³, Faye Chiu⁴, Priscilla Calvache⁵, Jillian Rose-Smith⁵, Andre Ogura⁶, Lucas Ogura Dantas⁶, Wambui Machua⁷, Julia Nguyen⁸, Lisa Mandl⁵, Hocine Tighiouart¹, Ludovic Trinquart², Iris Navarro-Millan⁹ and Sara Folta¹⁰, ¹Tufts Medical Center, Boston, MA, ²Tufts University School of Medicine, Boston, MA, ³N/A, West Orange, NJ, ⁴N/A, New York, NY, ⁵Hospital for Special Surgery, New York, NY, ⁶Ambulomics, Arlington, MA, ⁷Piedmont Healthcare, Atlanta, GA, ⁸Hospital for Special Surgery, New York, ⁹Weill Cornell Medicine, Hospital for Special Surgery, Poughkeepsie, NY, ¹⁰Tufts Friedman School of Nutrition, Boston, MA
Background/Purpose: Fatigue is a highly prevalent and debilitating symptom affecting up to 90% of individuals living with systemic lupus erythematosus (SLE). Despite its significant impact,…
Abstract Number: 2410 • ACR Convergence 2025
Immune Cell/Pathway-Specific Polygenic Risk Scores Reveal Immune Pathway Associations in Childhood-Onset Lupus Nephritis
Liyoung Kim¹, Daniela Fernandez-Salinas², Gonzalo Villanueva Martin³, Vitor Aguiar³, Laura Lewandowski⁴, Tiphanie Vogel⁵, Carola Vinuesa⁶, Linda Hiraki⁷, Tracey Wright⁸, Virginia Pascual⁹, Joyce Chang², Maria Gutierrez-Arcelus² and Peter Nigrovic¹, ¹Boston Children's Hospital, Brookline, MA, ²Boston Children's Hospital, Boston, MA, ³Boston Children's Hospital, Boston, ⁴NIAMS, NIH, Bethesda, MD, ⁵Baylor College of Medicine, Houston, TX, ⁶Francis Crick Institute, London, United Kingdom, ⁷The Hospital for Sick Children, Toronto, ON, Canada, ⁸UT Southwestern, Children's Medical Center, and Scottish Rite for Children, Dallas, TX, ⁹Weill Cornell Medical College, New York, NY
Background/Purpose: Polygenic risk scores (PRS) quantify an individual’s genetic susceptibility to diseases by integrating genotype data across multiple loci. However, conventional PRS are limited in…
Abstract Number: 2392 • ACR Convergence 2025
Does Obesity Influence Disease Activity and Biomarkers in Systemic Lupus Erythematosus Patients?: A Retrospective Study
Daniyal Nadeem¹, Anusheh Ali², Shravya Balmuri², Megan Mattison³, Upasana Agrawal⁴, Alexandra Zamora-Smith⁵, Karan Sachdeva⁶, Teresa leeth¹, Robert Quinet⁷, William Davis⁸, Jerald Zakem⁹, Chandana Keshavamurthy¹⁰, Xin Zhang¹¹, Sarwat Umer¹² and Samina Hayat¹³, ¹Louisiana State University Health Science, Shreveport, LA, ²Louisiana State University, Shreveport, LA, ³Louisiana State University- Shreveport, Shreveport, LA, ⁴Louisiana State University Health Sciences, Shreveport, Shreveport, LA, ⁵LSU Health Science Center in Shreveport, Shreveport, LA, ⁶Louisiana state university health shreveport, shreveport, ⁷Department of Rheumatology, Ochsner Health, New Orleans, LA, ⁸Ochsner Health System, New Orleans, LA, ⁹Ochsner Health Systems, Metairie, LA, ¹⁰banner university medical center, phoenix, AZ, ¹¹Ochsner Medical Center, New Orleans, LA, ¹²LSUHSC Shreveport, Shreveport, LA, ¹³Louisiana state university Shreveport, Shreveport, LA
Background/Purpose: Obesity, a prevalent condition, is known to exacerbate inflammation and could potentially influence the progression and severity of autoimmune diseases like Systemic lupus erythematosus…
Abstract Number: 2293 • ACR Convergence 2025
CLN-978, a CD19 x CD3-Directed T Cell Engager, Leads to Rapid and Deep B Cell Depletion In Vitro and In Vivo, Supporting Clinical Development Across Multiple Autoimmune Diseases
Ella Ioffe, Karsten Sauer, Todd Shearer, Jennifer Michaelson, Jeffrey Jones, Yue Zhang, Stephen Wax and Antoine Sreih, Cullinan Therapeutics Inc, Cambridge, MA
Background/Purpose: Treatments depleting CD19-expressing B cells have shown benefit in a range of autoimmune diseases. T cell engagers (TCE) offer off-the-shelf convenience, the predictable pharmacokinetic/pharmacodynamic…
Abstract Number: 2198 • ACR Convergence 2025
Sociocultural Influences on Pregnancy Planning for Individuals Diagnosed with SLE in an Urban Hispanic Population: A Qualitative Study with Considerations for a Holistic Approach
Andrew Ramirez¹, Alexa Montes de Oca¹, Martha Delgado¹, Mellissa withers¹ and Leanna Wise², ¹University of Southern California, Los Angeles, ²LAGMC/Keck Medicine of USC, Los Angeles
Background/Purpose: As systemic lupus erythematosus (SLE) often affects women of child-bearing age, understanding how this population makes reproductive health decisions is critical for well-rounded healthcare.…
Abstract Number: 1915 • ACR Convergence 2025
Innovative Clinical Trial Recruitment Approaches in Lupus Research: LuCIN Site Perspectives on Use of Social Media and Artificial Intelligence
Brandon Jackson¹, Roberto Caricchio², Saira Sheikh³, Meenakshi Jolly⁴, Jennifer Meriwether⁵, Taylor Irons⁶, Taylor Adjei⁷, Caroline Donovan⁸, Carla Menezes⁷, Courtney Canton⁹, Aimee Williams¹⁰, Maya Merrell⁹ and Stacie Bell¹¹, ¹Lupus Therapeutics, Miami, FL, ²University of Massachusetts Chan Medical School, Worcester, MA, ³University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁴Rush University, Chicago, IL, ⁵Lupus Therapeutics, Westminster, CO, ⁶Lupus Therapeutics, Houston, TX, ⁷Lupus Therapeutics, New York, NY, ⁸Lupus Therapeutics, Charlottesville, VA, ⁹Lupus Therapeutics, Charleston, SC, ¹⁰Lupus Therapeutics, Raleigh, NC, ¹¹Lupus Therapeutics, Lakewood, CO
Background/Purpose: Lupus disproportionately impacts racial and ethnic minorities, yet these groups remain underrepresented in clinical trials. Lupus Therapeutics, overseeing the Lupus Clinical Investigators Network (LuCIN),…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].